Ono Financial Statements From 2010 to 2024
| OPHLF Stock | USD 12.50 1.20 10.62% |
Check Ono Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ono Pharmaceutical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Ono financial statements analysis is a perfect complement when working with Ono Pharmaceutical Valuation or Volatility modules.
Ono |
Ono Pharmaceutical Co Company Return On Equity Analysis
Ono Pharmaceutical's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Ono Pharmaceutical Return On Equity | 0.16 |
Most of Ono Pharmaceutical's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ono Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Ono Pharmaceutical Co has a Return On Equity of 0.1605. This is 100.67% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The return on equity for all United States stocks is 151.77% lower than that of the firm.
Ono Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ono Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Ono Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ono Pharmaceutical competition to find correlations between indicators driving Ono Pharmaceutical's intrinsic value. More Info.Ono Pharmaceutical Co is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.75 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Ono Pharmaceutical Co is roughly 1.33 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ono Pharmaceutical's earnings, one of the primary drivers of an investment's value.About Ono Pharmaceutical Financial Statements
Ono Pharmaceutical stakeholders use historical fundamental indicators, such as Ono Pharmaceutical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Ono Pharmaceutical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ono Pharmaceutical's assets and liabilities are reflected in the revenues and expenses on Ono Pharmaceutical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ono Pharmaceutical Co. Please read more on our technical analysis and fundamental analysis pages.
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company was founded in 1717 and is headquartered in Osaka, Japan. Ono Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 3687 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Ono Pink Sheet
Ono Pharmaceutical financial ratios help investors to determine whether Ono Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ono with respect to the benefits of owning Ono Pharmaceutical security.